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Abstract
Background:  The autoimmune thyroid diseases (AITDs), comprising Graves' disease (GD) and
Hashimoto's thyroiditis (HT), appear to develop as a result of complex interactions between
predisposing genes and environmental triggers. Susceptibility to AITDs is conferred by genes in the
human leukocyte antigen (HLA) and genes unlinked to HLA, including the CTLA-4 gene. Recently,
an association to some estrogen receptor (ER)α  genotypes with breast cancer, hypertension,
osteoporosis,  generalized  osteoarthritis,  and  some  autoimmune  diseases  such  as  rheumatoid
arthritis has been reported. We have analyzed a dinucleotide (TA)n repeat polymorphism lying
upstream of the human ERα  gene in patients with AITDs and in normal subjects.
Results:  Seventeen different alleles were found in 130 patients with GD, 93 patients with HT, and
190 control subjects. There was no significant difference in the distributions of ERα  alleles between
patients and controls.
Conclusions:  The present results do not support an association between the ER α  gene and AITD
in the Japanese population.
Background
Autoimmune thyroid diseases (AITDs), including
Graves' disease (GD) and Hashimoto's thyroiditis (HT),
are the most common human autoimmune diseases and
are responsible for significant morbidity in premenopau-
sal women. AITDs are caused by immune responses to
the thyroid gland. In GD, the autoimmune process re-
sults in production of thyroid-stimulating antibodies and
leads to hyperthyroidism, whereas in HT, the end result
is thyroid cell death and hypothyroidism [1,2].
The pathogenesis of AITDs involves complex interac-
tions between genetic and environmental factors [3,4].
The genetic relations between GD and HT and the famil-
ial and sporadic forms of these diseases are unclear. This
problem, until now, has been addressed by studying a va-
riety of candidate genes, primarily via association stud-
ies. Because it has been assumed that immune
dysregulation and/or thyroid antigen presentation are
involved in AITD, the candidate genes that have been
tested comprised genes involved in immunoregulatory
pathways and genes encoding for the major thyroid au-
toantigens. These genes included the human leukocyte
antigen (HLA) [5], immunoglobulin H heavy chain [6], T
cell receptor [7], interleukin-1 receptor antagonist [8],
interferon-γ  [9], thyroid stimulating hormone receptor
[10,11], thyroid peroxidase [12], and cytotoxic T lym-
phocyte antigen-4 (CTLA-4) genes [13]. With the excep-
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tion of the HLA and CTLA-4 loci, the candidate genes
examined gave either negative or equivocal results. Re-
cently, the existence of an estrogen receptor (ER)α  gene
polymorphism has made clear, and its association to
some variant ERα  genotypes with breast cancer [14,15],
hypertension [16], osteoporosis [17,18], generalized os-
teoarthritis [19], and some autoimmune diseases such as
rheumatoid arthritis [20] has been reported.
The ERα  gene on chromosome 6q24-q27 is organized
into eight exons and seven introns extending over ap-
proximately 140 kilobases [21]. ERα  belongs to the nu-
clear hormone receptor superfamily and modulates the
transcription of target genes in response to estrogen, a
potent immunomodulatory hormone [22]. Estrogens ap-
pear to play a central role in the immune response and
immune-mediated diseases [22]. In view of the possible
role of estrogens in the pathogenesis of AITDs, we have
analyzed a dinucleotide (TA)n repeat polymorphism ly-
ing upstream of the human ERα  gene in patients with
AITDs and in normal subjects.
Results
Seventeen different alleles were found in 130 patients
with GD, 93 patients with HT, and 190 controls subjects.
The various alleles were designated as ERα *1 through
ER*α 17 according to their sizes, which ranged from 164
to 198 bp. The distribution of ERα  alleles in the three
groups is shown in Table 1. Allele frequencies in our GD
patients and our control subjects did not differ signifi-
cantly (Χ 2 = 15.49, 16 degrees of freedom, ρ  = 0.49). Al-
lele frequencies in our HT patients and our control
subjects also did not differ significantly (Χ 2 = 14.62, 16
degrees of freedom, ρ  = 0.55).
Discussion and Conclusions
ERα  belongs to the nuclear hormone receptor super-
family and modulates the transcription of target genes in
response to estrogen [22]. Recent studies have shown the
presence of ERα s on the cells involved in the immune re-
sponse, namely thymocyte, macrophages and endotheli-
al cells [22]. Particular attention has been focused on the
dose-dependent influence of estrogen on the immune re-
sponse, which appears to be related to the clinical symp-
toms of autoimmunity (i.e. the effects of pregnancy or
oral contraceptive pills) [22]. The influence of estrogens
on cytokine production by target cells, through interfer-
ence with their transcriptional activity, has also been the
focus of various studies [22]. The effect of estrogens on
the expression of the protooncogenes and oncosuppres-
sor genes involved in programmed cell death (apoptosis)
might also be relevant to human autoimmunity, in par-
ticular the uncontrolled synovial lining cell hyperplasia
associated with rheumatoid arthritis and the prolonged
T-cell survival in systemic lupus erythematosus [22].
Thus, we investigated the relation between a dinucle-
otide (TA)n repeat polymorphism lying upstream of the
human ERα  gene and AITDs. Our data did not appear to
indicate any association between the ERα  gene and the
AITDs analyzed. This result might indicate of a large di-
versity in the genetic background of AITDs, although this
Table 1: Allele frequencies of the ERα  gene polymorphism in patients with AITDs and in control subjects
Graves' disease Hashimoto's thyroiditis Controls
ERα  polymorphism n=130, (260 alleles), (%) n=93, (186 alleles), (%) n=190, (380 alleles), (%)
allele *1 20 (7.7%) 13 (7.0%) 24 (6.3%)
allele *2 40 (15.3%) 34 (18.3%) 88 (23.2%)
allele *3 49 (18.7%) 25 (13.4%) 58 (15.3%)
allele *4 32 (12.3%) 26 (14.0%) 39 (10.3%)
allele *5 7 (2.7%) 2 (1.1%) 13 (3.4%)
allele *6 10 (3.8%) 8 (4.3%) 12 (3.2%)
allele *7 19 (7.3%) 12 (6.5%) 23 (6.1%)
allele *8 10 (3.8%) 12 (6.5%) 16 (4.2%)
allele *9 15 (5.8%) 10 (5.4%) 23 (6.1%)
allele *10 11 (4.2%) 10 (5.4%) 15 (3.9%)
allele *11 17 (6.5%) 12 (6.5%) 37 (9.7%)
allele *12 14 (5.4%) 12 (6.5%) 18 (4.7%)
allele *13 10 (3.8%) 7 (3.8%) 10 (2.6%)
allele *14 5 (1.9%) 2 (1.1%) 2 (0.5%)
allele *15 1 (0.4%) 0 (0%) 1 (0.3%)
allele *16 0 (0%) 0 (0%) 1 (0.3%)
allele *17 1 (0.4%) 1 (0.5%) 0 (0%)
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observation deserves further analysis in a larger group of
AITD patients.
Materials and Methods
Subjects
One hundred and thirty unrelated Japanese women with
GD and 93 unrelated Japanese women with HT were in-
cluded in this study. GD was diagnosed on the basis of
clinical symptoms and biochemical confirmation of
hyperthyroidism, including diffuse goiter, ophthalmopa-
thy, elevated radioactive iodine uptake, and thyroid hor-
mone levels. HT patients had documented clinical and
biochemical hypothyroidism requiring thyroid hormone
replacement therapy and showed autoantibodies against
thyroid peroxidase with or without antibodies against
thyroglobulin. One hundred and ninety unrelated Japa-
nese women without clinical evidence or family history
of any autoimmune diseases were selected as normal
control subjects. The research protocol was approved by
the ethics committee of our hospital, and informed con-
sent was obtained from all patients and controls.
Determination of microsatellite polymorphism by 
polymerase chain reaction
Genomic DNA was isolated from whole blood with a
Genomix kit (Talent, Trieste, Italy). Microsatellite mark-
er loci were typed with fluorescence-based methods
[23,24]. The polymerase chain reaction (PCR) was per-
formed with oligonucleotide primers designed to amplify
a polymorphic (TA)n repeat at 1174-base pair upstream
of the human ERα  gene [18]. PCR was performed in a to-
tal volume of 20 µ l of the following mixture: 100 ng of
human genomic DNA; 5 pmol of each primer (Cy-5'-
GACGCATGATATACTTCACC-3' and 5'-GCAGAAT-
CAAATATCCAGATG-3'); 200 µ M of each dNTPs; 2 µ l of
10 ×  reaction buffer (Takara Shuzo Co., Kyoto, Japan);
and 1 unit of Taq DNA polymerase (Takara Shuzo Co.).
Thirty PCR cycles of 2 min at 94° C, 1 min at 58° C, and 1
min at 74° C were performed. The amplified fragments
were analysed by electrophoresis with an automatic DNA
sequencer using 8% or 6% polyacrylamide gels contain-
ing 7 M Urea (Amersham Pharmacia Biotech, Buckin-
gamshire, UK). The raw data were converted to
dinucleotide repeat polymorphic band patterns with the
use of a software program (Amersham Pharmacia Bio-
tech,). The length of TA repeat in each amplified product
was determined by comparison with a ladder of control
DNAs.
Statistical Analyses
Comparisons between the various alleles in patients with
AITDs and in controls were made with the Χ 2-test, and ρ
< 0.05 was considered significant. Fisher's exact test was
used when necessary. The relative risk was calculated by
Woolf's method [25].
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